<DOC>
	<DOCNO>NCT02645266</DOCNO>
	<brief_summary>Diabetic Macular Edema serious ocular consequence poorly control diabetes . Even though significant research do clarify pathogenesis DME , clear causal pathway complication yet undetermined . However , consensus among researcher cascade inflammatory marker play important role disease process . Here hope good delineate role inflammatory marker play investigate whether basal level predict response lack thereof Aflibercept .</brief_summary>
	<brief_title>Mean Visual Acuity Changes Following Five Injections Aflibercept</brief_title>
	<detailed_description />
	<criteria>1 . Diagnosis DME retina specialist 2 . Age : 18 old 3 . VA 25 75 letter baseline 4 . Treatment na√Øve 1 . Unwilling sign consent form 2 . Previous antiVEGF intravitreal treatment affect eye 3 . Actively take systemic steroid 4 . Ocular inflammatory disease autoimmune disease 5 . Previous laser treatment DME within last 3 month ( washout period laser treatment inflammation approximately 3 month . 6 . Any ocular surgery within last 3 month . 7 . Previous retina surgery ( PPV , ERM surgery etc ) 8 . Medically uncontrolled glaucoma 9 . Any retinal condition ( CRAO , CRVO , wAMD , geographic atrophy ) 10 . Individuals physical mental disability prevent accurate vision test 11 . Proliferative diabetic retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>